4 results about "Alternative therapy" patented technology

The present invention provides a novel use and methods comprising antibodies, or antigen-binding fragments thereof, which bind to a CCR7 receptor for use as a novel therapeutic agent in prevention and / or treatment of graft versus host disease (GVHD), preferably in hematopoietic stem cell transplantation (HSCT), more preferably allogeneic hematopoietic stem cell transplantation. GVHD of the invention can be acute (aGVHD) and / or chronic (cGVHD), preferably acute. The antibodies and antigen-binding fragments are capable of selectively depleting ex vivo or in vitro immune cells expressing CCR7 and are capable in vivo of selectively killing immune cells expressing a CCR7 receptor and of impairing / blocking migration and of activation of said immune cells, which are involved in the development and evolution of GVHD. The use of said antibodies for depleting, killing and impairing / blocking migration and activation of immune cells expressing CCR7 cells is disclosed, thus providing an alternative therapy for preventing and treating GVHD in both acute and chronic types.

The aim is to provide technology that improves the precision of treatments in alternative medicine. [Solution] A treatment support system that supports treatment as alternative medicine for a person receiving treatment, comprising: a reaction acquisition unit that acquires reaction information showing the person receiving treatment's response to the practitioner's actions; an analysis unit that analyzes the reaction information using AI including a machine learning model to identify at least one of the affected area and the cause of the affected area; and an output unit that outputs the analysis results from the analysis unit.

To provide alternative treatments for subjects suffering from diseases, disorders, and conditions related to the oxalate pathway. [Solution] The present invention relates to a double-stranded ribonucleic acid (dsRNA) composition that targets the LDHA gene, a method for inhibiting LDHA expression, a method for inhibiting LDHA and HAO1 using such a dsRNA composition, and a method for treating subjects who may benefit from reduced LDHA expression, for example, subjects suffering from diseases, disorders or conditions related to the oxalate pathway.

A method for recommending therapy includes identifying a group of one or more individuals that have stopped using or have not started using a respiratory therapy device, collecting data associated with each of the one or more individuals, and, for each respective individual, determining whether to recommend an alternative therapy based on the data associated with the respective individual. A method for monitoring an individual who is using a mandibular repositioning device (MRD) includes receiving data associated with the individual during a period of time where the individual used the MRD during one or more sleep sessions, analyzing the data to determine a readiness of the individual to transition from the use of the MRD to an alternative therapy, and based on the analysis, transmitting a recommendation to the individual to (i) transition to the alternative therapy and discontinue using the MRD, or (ii) continue using the MRD.